Liminatus Pharma, Inc.
PublicLiminatus Pharma, Inc. is now publicly traded
The data on this page reflects Liminatus Pharma, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Warrant Exercise
Jun 3, 2026
Total Funding Raised
$1.86M
Company Overview
Liminatus Pharma, Inc. is based in FULLERTON. It has raised $1.86M.
Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company that develops novel immune-modulating cancer therapies, including CD47-blockade antibodies and cancer vaccines.
AI Layer
Application
Liminatus Pharma, Inc. Comparables
Compare Liminatus Pharma, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InnoBation Bio | 86% | |
| Link Cell Therapies | 69% | |
| Ascendo Biotechnology | 59% |
For institutional investors. Book with your work email.
Liminatus Pharma, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Warrant Exercise | Jun 3, 2026 |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_valuationAug 24, 2026
Liminatus Pharma, Inc. has a $6.4M market cap in California on Aug 24th '26, while its shares trade at $4.73 after falling 8.2%.
- partners_withAug 24, 2026
Liminatus Pharma, Inc. engages Synex Consulting Ltd. to support clinical development of IBC101 in South Korea through a milestone-based clinical research program, as announced in California on Aug 24th '26.
For institutional investors. Book with your work email.
Liminatus Pharma, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.